The Management of Helicobacter Pylori
References
1. Zantan SJ, Bradette M, Parley A et al. The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using Omeprazole based triple therapy. Alimen Pharmacol Ther 1999;13(3):289-95
2, Wong BC, Lam SK, Lai KC et al. Triple therapy for Helicobacter pylori eradication is more effective than long term maintenance anti-secretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study. Aliment Pharmacol Ther 1999;13(3):303-9
3. Marshall B, Warren J. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983:1273-5
4. NIH consensus development panel on Helicobacter pylori in peptic ulcer disease. J Am Med Assoc. 1994:272:65-9
5. The report of the Digestive Health Initiative SM International Update Conference on Helicobacter pylori. Gastroenterology 1997;113 Suppl 6:S4-8
6. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998;93:2330-8
7. Hunt RH, Thomson AB. Canadian Helicobacter pylori consensus conference. Canadian Association of Gastroenterology. Can J Gastroenterol 1998;12:31-41
8. Hunt RH, Fallone CA, Thomson AB. Canadian Helicobacter pylori conference consensus update: infections in adults. Canadian Helicobacter study group. Can J Gastroenterol 1999:13:213-7
9. Current European concepts in the management of Helicobacter pylori infections. The Maastricht Consensus Report. The European Helicobacter pylori Study Group. Gut 1997:41:8-13
10. Lam SK, Tally NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998;1 3:1-12
11. Bazzoli F, Zagari RM, Fossi et al. Efficacy and tolerability of a short term, low dose therapy for eradication of Helicobacter pylori. Gastroenterology 1993;104:A40
12. Lind T, Van Zanten SV, Unge P, Spiller R et al. Eradication of Helicobacter pylori using one-week triple therapies combining Omeprazole with two antimicrobials: the MACH 1 study. Helicobacter 1996:3:138-44
13. Lind T, Van Zanten SV, Unge P et al. The MACH 2 study: role of Omeprazole in eradication of Helicobacter pylori with one-week triple therapies. Gastroenterology 1999:116:248-53
14. Ell C, Schooner C, Solbach W et al. The AMOR study: a randomized, double blind trial of Omeprazole versus ranitidine together with Amoxycillin and Metronidazole for eradication of Helicobacter pylori. Eur ) Gastroenterol Hepatol 2001;13(6):685-91
15. Wong BC, Chang FY, Abid S et al. Triple therapy with Clarithromycin, Omeprazole and Amoxycillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. Aliment Pharmacol Ther 2000:14(11):1 529-35
16. Miwa H, Ohkura R, Murai T et al. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection- comparison with Omeprazole and lansoprazole. Aliment Pharmacol Ther 1999;13(6):741-6
17. Lee JM, Breslin NP, Hyde DK et al. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther 1999:13(4):489-96
18. Savarino V, Zentilin P, Bisso G et al. Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and Metronidazole in the eradication of Helicobacter pylori. Aliment Pharmacol Ther 1999:13:43-7
19. Cammarota G, Cannizzaro 0, Ojetti V et al. Five-day regimens containing ranitidine ismuth citrate plus high dose clarithromycin and either Amoxycillin or tinidazole for Helicobacter pylori infection. Aliment Pharmacol Ther 2000:14:73-77
20. Neville PM, Everett S, Langworthy H et al. The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen. Aliment Pharmacol Ther 1999:13:497-501
21. O'Connor HJ, Mcloughlin R, Kelly S et al. Lansoprazole triple therapy for Helicobacter pylori: Is 5 days enough? Aliment Pharmacol Ther 1998:12:273-6
22 Meyer JM, Silliman NP, Wang Wet al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study 1993-1999. Ann Intern Med 2002;136(1):13-24
23 Osato MS, Reddy RMS, Reddy SG et al. Pattern of primary resistance of Helicobacter pylori to Metronidazole or clarithromycin in the United States. Arch Intern Med 2001:1 61 (9):1 21 7-1220
24. Annibale B, D'Ambra G, Luzzi I et al. Does pretreatment with omeprazole decrease the chance of eradication of Helicobacter pylori in peptic ulcer patients. Am J Gastroenterol 1997:92(5):790-4
25. Ling TK, Cheng AF, Sung JJ, Yiu PY, Chung SS. An increase in Helicobacter pylori starins resistant to metronidazole: a five-year study. Helicobacter 1996;1(1):57-61
26. Lopez-Brea M, Domingo D, Sanchez I, Alarcon T. Evolution of resistance to metronidazole and claritromycin in Helicobacter pylori clinical isolates from Spain. J Antimicrobial Chemother 1997;40(2):279-81
27. Katelaris PH, Adamthwaite D, Midolo P et al. Randomized trial ofomeprazole and metronidazole with amoxycillin or clarithromycin for Helicobacter pylori eradication, in a region of high primary metronizole resistance: the HERO study. Aliment Pharmacol Ther 2000; 14(6):751-8
28. Van der Wouden Ej, Thijs )C, Zwet AA, Kooy A, Kleibeuker JH. The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection. Aliment Pharmacol Ther 1999;13(2):297-302
29. Savarino V, Zentilin P, Pivari M et al. The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. Aliment Pharmacol Ther 2000; 14(7):893-900
30. Tankovic J, Lamarque D, Lascols S, Soussy CJ, Delchier JC. Clarithromycin resistance of Helicobacter pylori has a major impact on the efficacy of the omeprazole-amoxycillin-clarithromycin therapy. Pathologie et Biologic 2001;47(7):528-33
31. Huang AH, Sheu BS, Yang HB et al. Impact of Helicobacter pylori antimicrobial resistance on the outcome of 1-week lansoprazole-based triple therapy. J Forinosan Medical Assoc. 2000;99(9):704-9
32. Wong BC. Impact of primary antibiotic resistance on outcome 2001
33. Hoshiya S, Watanabe K, Tokunnaga K et al. Relationship between eradication therapy and clarithromycin resistant Helicobacter pylori in Japan. J Gastroenterol 2000;35(1):10-4
34. Adarnek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W. Primary and acquired Helicobacter resistance to clarithromycin, metronidazole and amoxycillin - influence on treatment outcome. Am J Gastroenterol 1998;93:386-9
35. Pilotto A, Franceschi M, Rassu M et al. Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study. Dig Liver Dis 2000;32(8):667-72
36. Megraud F, Pichavant R, Palegry D et al, Ranitidine bismuth citrate co-prescribed with clarithromycin is more effective in eradication of Helicobacter pylori than omeprazole with clarithromycin. Gut 1997;41 suppl 1:A92
37. Osato M, Graham DY, Vakil N et al. Development of clarithromycin resistance is 2.7 times less likely with ranitidine bismuth citrate than omeprazole. Gastroenterology 1998:114:A249
38. Broutet N, Tchamgoue S, Pereira E, Megraud F. Risk factors for failure of Helicobacter pylori eradication therapy. In: Hunt RH, Tytgat GN). Helicobacter pylori: basic mechanism to clinical cure 2000; Kluwer 2000:601-7
39. Huang JQ, Hunt RH. Is one-week anti-H. pylori treatments more effective in patients with peptic ulcer disease (PUD) than in those with non-ulcer dyspepsia (NUD)? A meta-analysis. AmJ Gastroenterol 1998;93:1639
40. Kayser S, Flury R, Zbinder R et al. Comparative effect of lansoprazole / amoxycillin and omeprazole / amoxycillin for eradication of Helicobacter pylori in duodenal ulcer patients. Schweiz Med Wochenschr. 1997;127:722-7
41 . Lee JM, Fallen C, Breslin NP, Hyde DK. H. pylori eradication: quadruple therapy is effective in triple therapy failures. Gastroenterology 1997; 112:A195
42. Neville P, Barrowclough S, Moayyedi P. Second-line eradication for H. pylori after failure of therapy with proton pumpm inhibitor, clarithromycin and metronidazole: results of a case series. Ghastroenterology 1999;116:A266
43. Borda F, Martinez A, Echarri A et al. Clinical practice results of quadruple treatment in Helicobacter pylori eradication failure with OCA-7. Gut 1998;43 suppl 2:A81
44. Gomollon F, Ducons JA, Ferrero M et al. Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases. Helicobacter 1999;4:222-5
45. Perri F, Festa V, Clemente R et al. Randomized study of two "rescue" therapies for Helicobacter pylori infected patients after failure of standard triple therapies. Am J Gastroenterol 2001;96(1):58-62
46. Graham DY, Hoffman J, Osato M et al. New therapy for metronidazole or clarithromycin resistant Helicobacter pylori: FOC or FOM, Gastroenterology 1998;114:A138-9
47. De Boer WA, Tytgat GN). Treatment of Helicobacter pylori infection. Br
Med J 2000:320:31-4